Subscribe
shutterstock_560385427_quinta
Quinta / Shutterstock.com
25 November 2020GenericsRory O'Neill

EC plans to lower barriers to generic drugs

The European Commission wants to increase access to generic medicines and crack down on anti-competitive behaviour in the pharmaceutical industry, a new plan has said.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Chiesi blocks Japanese drugmaker’s new brand at EU General Court
1 July 2020   Japan-based Nitto Pharmaceutical Industries has been blocked from using its ‘Noster’ brand in the EU, in a win for Italian drugmaker Chiesi Farmaceutici.
Generics
EU adopts SPC manufacturing waiver
16 May 2019   The European Union has adopted the proposed supplementary protection certificate manufacturing waiver, despite criticism from parts of the pharmaceutical industry.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

AIPPI: Personalised medicine tests the limits in patent law
Ropes & Gray loses 21-attorney group to join rival on growth spree
How 'Boehringer' sets preliminary relief threshold for generics
‘Whose trademark law is AI based on exactly?’: Key questions from Marques
The Quintara decision: Defining trade secrets in federal cases
To disclose or not: Pharma patents face new AI reality
Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths